Natarajan Muthusamy Selected Research

milatuzumab

1/2013	Milatuzumab-conjugated liposomes as targeted dexamethasone carriers for therapeutic delivery in CD74+ B-cell malignancies.
4/2012	Dual-targeting immunotherapy of lymphoma: potent cytotoxicity of anti-CD20/CD74 bispecific antibodies in mantle cell and other lymphomas.
12/2011	FTY720 increases CD74 expression and sensitizes mantle cell lymphoma cells to milatuzumab-mediated cell death.
4/2011	Combination anti-CD74 (milatuzumab) and anti-CD20 (rituximab) monoclonal antibody therapy has in vitro and in vivo activity in mantle cell lymphoma.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Natarajan Muthusamy Research Topics

Disease

49	Neoplasms (Cancer) 01/2022 - 12/2002
36	B-Cell Chronic Lymphocytic Leukemia (Chronic Lymphocytic Leukemia) 10/2022 - 08/2006
15	Leukemia 01/2021 - 08/2006
8	Acute Myeloid Leukemia (Acute Myelogenous Leukemia) 01/2022 - 06/2009
8	Lymphoma (Lymphomas) 10/2012 - 10/2007
7	Precursor Cell Lymphoblastic Leukemia-Lymphoma (Acute Lymphoblastic Leukemia) 01/2022 - 09/2007
7	Mantle-Cell Lymphoma (Lymphoma, Mantle Cell) 01/2021 - 06/2010
4	B-Cell Lymphoma (Lymphoma, B Cell) 01/2021 - 01/2008
4	Breast Neoplasms (Breast Cancer) 01/2020 - 01/2016
3	Hematologic Neoplasms (Hematological Malignancy) 01/2018 - 01/2013
3	Bronchiolitis Obliterans Syndrome 01/2016 - 11/2014
3	Non-Hodgkin Lymphoma (Lymphosarcoma) 09/2013 - 04/2008
2	Melanoma (Melanoma, Malignant) 01/2020 - 01/2016
2	Myelodysplastic Syndromes (Myelodysplastic Syndrome) 01/2018 - 09/2017
2	Lymphoproliferative Disorders (Lymphoproliferative Disorder) 10/2012 - 04/2008
2	Multiple Sclerosis 12/2011 - 09/2007
2	Hepatocellular Carcinoma (Hepatoma) 06/2011 - 02/2008
1	Disease Progression 01/2019
1	Rectal Prolapse 01/2019
1	Colitis 01/2019
1	Renal Cell Carcinoma (Grawitz Tumor) 01/2018
1	Glioblastoma (Glioblastoma Multiforme) 01/2018
1	Pancreatic Neoplasms (Pancreatic Cancer) 01/2018
1	T-Cell Leukemia (Leukemia, T Cell) 01/2018
1	Parasitic Diseases (Parasitic Disease) 10/2013
1	Communicable Diseases (Infectious Diseases) 10/2013

Drug/Important Bio-Agent (IBA)

11	Proteins (Proteins, Gene)FDA Link 01/2021 - 10/2002
9	Fingolimod Hydrochloride (FTY720)FDA Link 09/2015 - 09/2007
8	ibrutinibIBA 01/2022 - 10/2013
7	Pharmaceutical PreparationsIBA 01/2016 - 08/2006
6	AntibodiesIBA 10/2022 - 10/2007
6	Monoclonal AntibodiesIBA 01/2020 - 03/2009
6	Lenalidomide (CC 5013)FDA Link 01/2016 - 10/2008
6	Rituximab (Mabthera)FDA Link 03/2013 - 05/2008
5	OSU-2SIBA 01/2022 - 06/2011
5	Agammaglobulinaemia Tyrosine KinaseIBA 01/2022 - 10/2013
5	interleukin-21 (interleukin 21)IBA 01/2020 - 05/2008
4	RNA (Ribonucleic Acid)IBA 10/2020 - 06/2009
4	CytokinesIBA 01/2018 - 02/2011
4	milatuzumabIBA 01/2013 - 04/2011
4	OligonucleotidesIBA 01/2013 - 06/2009
3	mouse MIRN29 microRNAIBA 01/2019 - 06/2009
3	Biological ProductsIBA 09/2013 - 09/2010
3	MicroRNAs (MicroRNA)IBA 06/2012 - 06/2009
3	fludarabineIBA 05/2008 - 08/2006
2	Phosphotransferases (Kinase)IBA 02/2018 - 09/2007
2	Interleukin-10 (Interleukin 10)IBA 01/2018 - 12/2015
2	Interleukin-21 ReceptorsIBA 01/2016 - 06/2015
2	Granulocyte Colony-Stimulating Factor (G-CSF)IBA 01/2016 - 01/2016
2	emt protein-tyrosine kinase (IL2-inducible T-cell kinase)IBA 01/2016 - 11/2014
2	OligodeoxyribonucleotidesIBA 06/2015 - 02/2010
2	Cytarabine (Cytosar-U)FDA LinkGeneric 06/2015 - 02/2010
2	Antisense OligonucleotidesIBA 06/2015 - 01/2009
2	TetraspaninsIBA 01/2015 - 09/2013
2	Interleukin-2 (IL2)IBA 11/2014 - 01/2010
2	AntigensIBA 11/2013 - 02/2010
2	Transferrin (beta 2 Transferrin)IBA 05/2013 - 02/2010
2	Liposomes (Liposome)IBA 01/2013 - 04/2008
2	Immunoglobulin G (IgG)IBA 04/2012 - 03/2009
2	Cyclin D1IBA 12/2011 - 06/2010
2	Immunosuppressive Agents (Immunosuppressants)IBA 06/2011 - 02/2008
2	Reactive Oxygen Species (Oxygen Radicals)IBA 04/2011 - 07/2010
2	Therapeutic UsesIBA 02/2010 - 06/2009
2	Messenger RNA (mRNA)IBA 01/2010 - 01/2009
2	DNA (Deoxyribonucleic Acid)IBA 06/2009 - 12/2002
1	CTLA-4 AntigenIBA 01/2022
1	Phosphoric Monoester Hydrolases (Phosphatases)IBA 01/2022
1	Protein Phosphatase 2 (Protein Phosphatase 2A)IBA 01/2022
1	venetoclaxIBA 01/2021
1	Receptor Tyrosine Kinase-like Orphan ReceptorsIBA 01/2021
1	Immunoconjugates (Immunoconjugate)IBA 01/2021
1	EnzymesIBA 01/2020
1	BI-1347IBA 01/2020
1	idelalisibIBA 01/2019
1	BI 6727IBA 02/2018
1	BI 836858IBA 02/2018
1	Diphtheria ToxinIBA 01/2018
1	tagraxofuspIBA 01/2018
1	Interleukin-3 (Interleukin 3)IBA 01/2018
1	Fc Receptors (Fc Receptor)IBA 01/2018
1	Interleukin-3 Receptors (Interleukin 3 Receptor)IBA 01/2018
1	Tumor Suppressor Proteins (Proteins, Tumor Suppressor)IBA 01/2018
1	Mitogen-Activated Protein KinasesIBA 11/2017
1	withaferin AIBA 09/2017
1	acalabrutinibIBA 08/2017
1	Chimeric Antigen ReceptorsIBA 03/2016
1	NK Cell Lectin-Like Receptor Subfamily CIBA 01/2016
1	monalizumabIBA 01/2016
1	Ribonucleotide Reductases (Ribonucleotide Reductase)IBA 06/2015
1	GTI2040IBA 06/2015
1	Lipid NanoparticlesIBA 06/2015
1	ocaratuzumabIBA 05/2014
1	Small Interfering RNA (siRNA)IBA 11/2013
1	Immunoglobulins (Immunoglobulin)IBA 11/2013

Therapy/Procedure

31	Therapeutics 10/2022 - 10/2007
5	Immunotherapy 01/2022 - 04/2010
4	Drug Therapy (Chemotherapy) 01/2021 - 02/2010
1	Euthanasia (Mercy Killing) 01/2019
1	Cell Transplantation 01/2018
1	Hematopoietic Stem Cell Transplantation 11/2014